Global Monoclonal Antibodies Market- By Source, By Indication, By End User, By Application, By Production Type- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032

Description

Global Monoclonal Antibodies Market Overview:

According to SPER Market Research, the Global Monoclonal Antibodies Market is estimated to reach USD 604.06 billion by 2032 with a CAGR of 11.33%.

Monoclonal antibody (mAb) treatment is a type of immunotherapy that makes use of monoclonal antibodies to bind precisely to particular proteins or cells. The identical immune cells that make up monoclonal antibodies serve as copies of a distinct parental cell. These antibodies have monovalent affinity, which enables them to attach to a specific antigen when delivered. Due to their site-specificity, monoclonal antibodies are valuable tools for drug detection and purification and have significant applications in molecular biology, biochemistry, and medicine.

The market is primarily driven by an increase in the prevalence of cancer, an increase in the demand for biosimilar monoclonal antibodies that are less expensive, high demand for biologics, an increase in genomics R&D activities, and the introduction of technologically cutting-edge genetic platforms like next-generation sequencing. Additionally, a rise in research partnerships for the creation of a strong drug pipeline, increased patient and physician awareness of the uses of monoclonal antibody (mAb) therapy, and an increase in the approval of blockbuster mAbs for a number of applications all contribute to the market's expansion. The utilization of cutting-edge genetic engineering technology in the production of mAbs, the presence of well-developed healthcare infrastructure, government support for infection control & management, and an increase in the incidence of diseases linked to a sedentary lifestyle are additional factors driving market expansion. However, it is anticipated that low demand in developing nations may limit the market's expansion for monoclonal antibodies. On the other hand, throughout the projection period, growth possibilities in developing markets are anticipated to provide profitable potential.

The monoclonal antibody and pharmaceutical drug markets in the USA are governed by the Food and Drug Administration (FDA), a federal department of the US Department of Health and Human Services. The USFDA's regulatory support for the treatment of uncommon illnesses and rising product releases are anticipated to fuel the expansion of the monoclonal antibody therapeutics market.

Impact of COVID-19 on the Global Monoclonal Antibodies Market

The COVID-19 outbreak was deemed an international public health emergency by the World Health Organization (WHO) on January 30, 2020. A total of 210 nations throughout the world have been impacted by COVID-19. An unprecedented worldwide public health threat, COVID-19 is expected to have a favourable effect on the market for monoclonal antibodies and the development of monoclonal antibody treatment. The fast creation of several SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) neutralising monoclonal antibodies was driven by the realisation of the urgent need for medicines to be accessible on a worldwide scale (mAbs). Therefore, throughout the projection period, COVID-19 infection increased growth and possibilities for major players of monoclonal antibodies.

Scope of the Report:

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Source, By Indication, By End User, By Application, By Production Type

Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered Abbott Laboratories, AbbVie, AbGenomics, ADC Therapeutics, Agensys, Alexion Pharmaceuticals, ALMAC Group, Ambrx, Amgen, Astellas Pharma, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Celgene, Celldex Therapeutics, Daiichi Sankyo Company ltd., Eli Lilly, GenScript, GlaxoSmithKline Plc, Hoffman Roche Ltd, Johnson & Johnson, Merck & Co. Inc., Mylan N.V, Norvatis AG, Novo Nordisk A/S, Pfizer Inc, Sanofi, Seattle genetics, Shanghi Junsi bioscience ltd, Sigma-Aldrich Co. LLC, Teva pharmaceutical industries, Thermofischer Scientific.

Global Monoclonal Antibodies Market Segmentation:

By Source: Based on the Source, Global Monoclonal Antibodies Market is segmented as; Murine, Chimeric, Humanized and Human.

By Indication: Based on the Indication, Global Monoclonal Antibodies Market is segmented as; Cancer (Breast cancer, Colorectal cancer, Lung cancer, Ovarian cancer, Others), Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Others.

By End User: Based on the End User, Global Monoclonal Antibodies Market is segmented as; Hospitals, Research Institutes, Others.

By Application: Based on the Application, Global Monoclonal Antibodies Market is segmented as; Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular and Cerebrovascular, Others.

By Production Type: Based on the Production Type, Global Monoclonal Antibodies Market is segmented as; In Vivo and In Vitro.

By Region: The availability of a highly established healthcare infrastructure, strong patient awareness, and expanding opportunities for cancer research, among other reasons, contributed to North America having the greatest market share.

Product Code: BIOT2237

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER's internal database
- 2.1.4 Premium insight from KOL's
2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Monoclonal Antibodies Market

5. Market variables and outlook

5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
5.3. PORTER'S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Global Monoclonal Antibodies Market, By Source, 2019-2032 (USD Million)

6.1 Murine
6.2 Chimeric
6.3 Humanized
6.4 Human

7. Global Monoclonal Antibodies Market, By Indication, 2019-2032 (USD Million)

7.1 Cancer
- 7.1.1 Breast cancer
- 7.1.2 Colorectal cancer
- 7.1.3 Lung cancer
- 7.1.4 Ovarian cancer
- 7.1.5 Others
7.2 Autoimmune Diseases
7.3 Inflammatory Diseases
7.4 Infectious Diseases
7.5 Others

8. Global Monoclonal Antibodies Market, By End User, 2019-2032 (USD Million)

8.1 Hospitals
8.2 Research Institutes
8.3 Others

9. Global Monoclonal Antibodies Market, By Application, 2019-2032 (USD Million)

9.1 Anti-Cancer
9.2 Immunological
9.3 Anti-Infective Monoclonal Antibodies (MAbs)
9.4 Neuropharmacological
9.5 Cardiovascular And Cerebrovascular
9.6 Others

10. Global Monoclonal Antibodies Market, By Production Type, 2019-2032 (USD Million)

10.1 In Vivo
10.2 In Vitro

11. Global Monoclonal Antibodies Market, By Region, 2019-2032 (USD Million)

11.1 North America
- 11.1.1. United States
- 11.1.2. Canada
- 11.1.3. Mexico
11.2 Europe
- 11.2.1. Germany
- 11.2.2. United Kingdom
- 11.2.3. France
- 11.2.4. Italy
- 11.2.5. Spain
- 11.2.6. Rest of Europe
11.3 Asia-Pacific
- 11.3.1. China
- 11.3.2. Japan
- 11.3.3. India
- 11.3.4. Australia
- 11.3.5. South Korea
- 11.3.6. Rest of Asia-Pacific
11.4 South America
- 11.4.1. Brazil
- 11.4.2. Argentina
- 11.4.3. Rest of South America
11.5 Middle East & Africa
- 11.5.1. Kingdom of Saudi Arabia
- 11.5.2. United Arab Emirates
- 11.5.3. Rest of Middle East & Africa

12. Company Profiles

12.1 Abbott Laboratories
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2 AbbVie
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3 AbGenomics
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4 ADC Therapeutics
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5 Agensys
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6 Alexion Pharmaceuticals
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7 ALMAC Group
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8 Ambrx
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9 Amgen
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10 Astellas Pharma
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11 AstraZeneca plc
- 12.11.1. Company details
- 12.11.2. Financial outlook
- 12.11.3. Product summary
- 12.11.4. Recent developments
12.12 Bayer AG
- 12.12.1. Company details
- 12.12.2. Financial outlook
- 12.12.3. Product summary
- 12.12.4. Recent developments
12.13 Bristol-Myers Squibb
- 12.13.1. Company details
- 12.13.2. Financial outlook
- 12.13.3. Product summary
- 12.13.4. Recent developments
12.14 Celgene
- 12.14.1. Company details
- 12.14.2. Financial outlook
- 12.14.3. Product summary
- 12.14.4. Recent developments
12.15 Celldex Therapeutics
- 12.15.1. Company details
- 12.15.2. Financial outlook
- 12.15.3. Product summary
- 12.15.4. Recent developments
12.16 Daiichi Sankyo Company ltd.
- 12.16.1. Company details
- 12.16.2. Financial outlook
- 12.16.3. Product summary
- 12.16.4. Recent developments
12.17 Eli Lilly
- 12.17.1. Company details
- 12.17.2. Financial outlook
- 12.17.3. Product summary
- 12.17.4. Recent developments
12.18 GenScript
- 12.18.1. Company details
- 12.18.2. Financial outlook
- 12.18.3. Product summary
- 12.18.4. Recent developments
12.19 GlaxoSmithKline Plc
- 12.19.1. Company details
- 12.19.2. Financial outlook
- 12.19.3. Product summary
- 12.19.4. Recent developments
12.20 Hoffman Roche Ltd
- 12.20.1. Company details
- 12.20.2. Financial outlook
- 12.20.3. Product summary
- 12.20.4. Recent developments
12.21 Johnson & Johnson
- 12.21.1. Company details
- 12.21.2. Financial outlook
- 12.21.3. Product summary
- 12.21.4. Recent developments
12.22 Merck & Co. Inc.
- 12.22.1. Company details
- 12.22.2. Financial outlook
- 12.22.3. Product summary
- 12.22.4. Recent developments
12.23 Mylan N.V
- 12.23.1. Company details
- 12.23.2. Financial outlook
- 12.23.3. Product summary
- 12.23.4. Recent developments
12.24 Norvatis AG
- 12.24.1. Company details
- 12.24.2. Financial outlook
- 12.24.3. Product summary
- 12.24.4. Recent developments
12.25 Novo Nordisk A/S
- 12.25.1. Company details
- 12.25.2. Financial outlook
- 12.25.3. Product summary
- 12.25.4. Recent developments
12.26 Pfizer Inc
- 12.26.1. Company details
- 12.26.2. Financial outlook
- 12.26.3. Product summary
- 12.26.4. Recent developments
12.27 Sanofi
- 12.27.1. Company details
- 12.27.2. Financial outlook
- 12.27.3. Product summary
- 12.27.4. Recent developments
12.28 Seattle genetics
- 12.28.1. Company details
- 12.28.2. Financial outlook
- 12.28.3. Product summary
- 12.28.4. Recent developments
12.29 Shanghi Junsi bioscience ltd
- 12.29.1. Company details
- 12.29.2. Financial outlook
- 12.29.3. Product summary
- 12.29.4. Recent developments
12.30 Sigma-Aldrich Co. LLC
- 12.30.1. Company details
- 12.30.2. Financial outlook
- 12.30.3. Product summary
- 12.30.4. Recent developments
12.31 Teva pharmaceutical industries
- 12.31.1. Company details
- 12.31.2. Financial outlook
- 12.31.3. Product summary
- 12.31.4. Recent developments
12.32 Thermofischer Scientific
- 12.32.1. Company details
- 12.32.2. Financial outlook
- 12.32.3. Product summary
- 12.32.4. Recent developments